Background Nine oral antithrombotic medications currently available in the United States
and Europe have been studied in clinical trials for secondary prevention of cardiac events …

Patients with acute coronary syndrome (ACS) represent a major clinical burden, because
they tend to experience recurrent ischemic events. Acute management of patients with ACS …

Objective We performed a network meta-analysis to investigate the optimal antithrombotic
regime by indirectly comparing new antithrombotic regimes (new P2Y12 inhibitors plus …

Background Oral anticoagulation in addition to antiplatelet treatment after an acute coronary
syndrome might reduce ischaemic events but increase bleeding risk. We performed a meta …

Patients surviving an acute coronary syndrome (ACS) remain at increased risk of ischemic
events long term. This paper reviews current evidence and guidelines for oral antiplatelet …

Antithrombotic treatment is a key component of secondary prevention following acute
coronary syndromes (ACS). Although dual antiplatelet therapy is standard therapy post …

Dual antiplatelet therapy (DAPT), the combination of aspirin and a P2Y12 inhibitor, given for
12 months remains the standard of care after presentation with acute coronary syndrome …

Mortality and morbidity in acute coronary syndromes (ACSs), caused principally by plaque
erosion or rupture leading to thrombus formation and myocardial ischemia, have been …

The residual risk of patients surviving until 1 year after acute coronary syndromes (ACS) is
still high, despite secondary prevention. The cornerstone of treatment of patients with ACS is …

Abstract Purpose of Review Stable and unstable ischemic heart disease are a growing
component in all facets of healthcare, including ER visits, hospitalizations, and financial …